23:48:51 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-22 Kvartalsrapport 2024-Q3
2024-08-23 Kvartalsrapport 2024-Q2
2024-06-05 Ordinarie utdelning ACUC 0.00 SEK
2024-06-04 Årsstämma 2024
2024-04-26 Kvartalsrapport 2024-Q1
2024-02-16 Bokslutskommuniké 2023
2023-11-30 Kvartalsrapport 2023-Q3
2023-10-02 Extra Bolagsstämma 2023
2023-08-31 Kvartalsrapport 2023-Q2
2023-05-05 Ordinarie utdelning ACUC 0.00 SEK
2023-05-04 Årsstämma 2023
2023-04-28 Kvartalsrapport 2023-Q1
2023-02-24 Bokslutskommuniké 2022
2022-11-11 Kvartalsrapport 2022-Q3
2022-08-12 Kvartalsrapport 2022-Q2
2022-05-06 Ordinarie utdelning ACUC 0.00 SEK
2022-05-04 Årsstämma 2022
2022-04-28 Kvartalsrapport 2022-Q1
2022-02-24 Bokslutskommuniké 2021
2021-11-12 Kvartalsrapport 2021-Q3
2021-08-11 Kvartalsrapport 2021-Q2
2021-04-29 Ordinarie utdelning ACUC 0.00 SEK
2021-04-28 Kvartalsrapport 2021-Q1
2021-04-28 Årsstämma 2021
2021-02-18 Bokslutskommuniké 2020
2020-11-13 Kvartalsrapport 2020-Q3
2020-08-28 Kvartalsrapport 2020-Q2
2020-05-13 Ordinarie utdelning ACUC 0.00 SEK
2020-05-12 Årsstämma 2020
2020-05-12 Kvartalsrapport 2020-Q1
2020-02-25 Bokslutskommuniké 2019
2019-11-19 Kvartalsrapport 2019-Q3
2019-08-16 Kvartalsrapport 2019-Q2
2019-05-17 Kvartalsrapport 2019-Q1
2019-04-26 Ordinarie utdelning ACUC 0.00 SEK
2019-04-25 Årsstämma 2019
2019-02-13 Bokslutskommuniké 2018
2018-11-22 Kvartalsrapport 2018-Q3
2018-08-31 Kvartalsrapport 2018-Q2
2018-04-25 Kvartalsrapport 2018-Q1
2018-03-22 Ordinarie utdelning ACUC 0.00 SEK
2018-03-21 Årsstämma 2018
2018-02-06 Bokslutskommuniké 2017
2017-11-09 Kvartalsrapport 2017-Q3
2017-08-30 Kvartalsrapport 2017-Q2
2017-05-15 Kvartalsrapport 2017-Q1

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriMedicinteknik
AcuCort är ett läkemedelsföretag. Bolaget har utvecklat och kommersialiserar läkemedlet Zeqmelit® som är en munfilm baserad på kortisonsubstansen dexametason, för snabb tillgänglighet och lindring vid bland annat svåra och akuta allergiska reaktioner. Målet är kommersialisering i EU, USA och på utvalda nyckelmarknader via licenstagare och distributörer. Bolaget har sitt huvudkontor i Lund.
2020-02-05 09:00:00

The BIO Europe Spring conference is Europe's largest springtime Biotech partnering event. In addition to partnering meetings, BIO Europe Spring in Paris, France offers an agenda of presenting companies, and AcuCort has been selected to present in the Biotech sessions on March 24-25th. The company will be presented by CEO Ann Gidner.

Furthermore, AcuCort is attending the BioStock Live investor event in Stockholm, Sweden, on February 13th. At the event, Ann Gidner will give a company presentation as well as participate in an interview. The event will be webcast live and the interview will be available on www.acucort.com.

"We are rapidly moving towards market authorization and commercialization of ISICORT®. It is of great importance to take our partnering dialogues forward, and I am most happy to represent AcuCort in these important forums for networking and collaboration. Having participated at BIO Europe since twenty years, I know the strength of this gathering", says Ann Gidner, interim CEO at AcuCort.

For more information, please contact
Ms Ann Gidner, interim CEO, AcuCort AB
Phone +46 723 151414
Email ann.gidner@acucort.se

 

 

About AcuCort AB (publ)
AcuCort develops and commercializes ISICORT®, a new fast-dissolving oral film to put on the tongue, based on a well-known cortisone substance - dexamethasone. ISICORT® is a smart product in a new, innovative, patented and user-friendly dosage form primarily for the treatment of severe and acute allergic reactions, croup in children and chemotherapy-induced nausea and vomiting (CINV). The bioequivalence study that forms the basis of the application for marketing approval in Europe was carried out with positive results and a national hybrid application has been submitted to the Swedish Medical Products Agency. Altogether, this strengthens the company's assessment that the time to commercialization of ISICORT® may be relatively short. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market in Sweden.

About BIO-Europe Spring

This European partnering conference brings together some 2,600 delegates to hold 15,000 one-to-one meetings on global licensing opportunities. The conference attracts a wide range of business leaders, including senior executives of leading biotech companies, business development teams from large and midsized pharmaceutical companies, investors and industry experts.

About BioStock

BioStock is a leading Nordic digital news and analytics service focusing on the life science sector. The BioStock Live event has invited investors participating, and is also live streamed and recorded, providing presentations and industry insights to a broad audience.